Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Use of Compassionate Ivermectin in the Management of Symptomatic Outpatients and Hospitalized Patients with Clinical Diagnosis of Covid-19 at the Centro Medico Bournigal and at the Centro Medico Punta Cana, Grupo Rescue, Dominican Republic, from May 1 to August 10, 2020

Morgenstern et al., J. Clinical Trials (date from preprint)
Nov 2020  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
Retrospective 3,099 outpatients treated with ivermectin in an ER. Of 2,706 treated on an outpatient basis, 18 were subsequently hospitalized, 2 in the ICU, and there was one death (0.04%).
The average treatment delay for patients treated on an outpatient basis was 3.6 days, compared to 6.9 days for hospitalized patients, and 7.8 days for ICU patients.
For the 300 late treatment hospitalized patients there was 3 deaths. For the 111 very late treatment ICU patients there was 34 deaths.
Morgenstern et al., 3 Nov 2020, peer-reviewed, 14 authors.
This PaperIvermectinAll
The Use of Compassionate Ivermectin in the Management of Symptomatic Outpatients and Hospitalized Patients with Clinical Diagnosis of Covid-19 at the Centro Medico Bournigal and at the Centro Medico Punta Cana, Grupo Rescue, Dominican Republic, from May 1 to August 10, 2020
José Morgenstern, José N Redondo, Albida De León, Juan Manuel Canela, Nelson Torres Castro, Johnny Tavares, Miguelina Minaya, Óscar López, Ana Castillo, Ana María Plácido, Rafael Peña Cruz, Yudelka Merette, Marlenin Toribio, Juan Asmir Francisco, Santiago Roca
No antiviral has been shown to reduce mortality in SARS-COV-2 patients to date. In the present Retrospective observational study, 3,099 patients with a definitive or highly probable diagnosis of infection due to COVID-19 were evaluated between May 1st to August 10th, 2020, at the Centro Medico Bournigal (CMBO) and the Centro Medico Punta Cana (CMPC), and all received compassionate treatment with Ivermectin and Azithromycin. A total of 2,706 (87.3%) were discharged for outpatient treatment, all with mild severity of the infection. The average between the onset of symptoms and the Emergency Room (ER) visit in outpatients was 3.6 days (Early Treatment). In 2,688 (99.33%) with outpatient treatment, the disease did not progress to warrant further hospitalization and there were no deaths. In 16 (0.59%) with outpatient treatment, it was necessary their subsequent hospitalization to a room without any death. In 2 (0.08%) with outpatient treatment, it was necessary their admission to the Intensive Care Unit (ICU) and 1 (0.04%) patient died. There were 411 (13.3%) patients hospitalized, being admitted at a COVID-19 room with a moderate disease 300 (9.7%) patients of which 3 (1%) died; and with a severe to critical disease were hospitalized in the ICU 111 (3.6%), 34 (30.6%) of whom died. The mortality percentage of patients admitted to the ICU of 30.6% is similar with the percentage found in the literature of 30.9%. Total mortality was 37 (1.2%) patients, which is much lower than that reported in world statistics, which are around 3%, by the time of completion of this study.
Caly, Agstaff, Jans, Nuclear trafficking of proteins from RNA viruses: Potential targets for anti-virals?, Antiviral Res, doi:10.1016/j.antiviral.2012.06.008
Caly, Druce, Catton, Jans, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, doi:10.1016/j.antiviral.2020.104787
Cellina, Orsi, Pittino, Toluian, Oliva, Chest computed tomography findings of COVID-19 pneumonia: Pictorialessay with literature review, J Radiol, doi:10.1007/s11604-020-01010-7
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wahan, China: A descriptive study, doi:10.1016/s0140-6736(20)30211-7
Diego, Inhibition of NF-kB mediated inflammation in severe acute respiratory syndrome coronavirus infected mice increases survival, J virol, doi:10.1128/jvi.02576-13
Gandhi, Lynch, Rio, Clinical practice mild or moderate Covid-NEJM
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/s0140-6736(20)30183-5
Khater, Das, Reposing ivermectin to inhibit the activity of SARS CoV2 helicase: Possible implications for COVID 19 therapeutics
Moore, June, Cytokine release syndrome in severe COVID-19
Morgenstern, None, J Clin Trials
Morgenstern, Redondo, Leon, Canela, Torres et al., Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding, Lancet
Pujadas, Chaudhry, Mcbride, Richter, Zhao et al., SARS-CoV-2 viral load predicts COVID-19 mortality
Ratzinger, Haslacher, Poeppl, Hoermann, Kovarik et al., Azithromycin suppresses CD4 (+) T-cell activation by direct modulation of mTOR activity, Sci Rep, doi:10.1038/srep07438
Riccò, Ferraro, Gualerzi, Ranzieri, Henry et al., Point of care diagnostic tests for detecting SARS-CoV-2 antibodies: A systematic review and meta-analysis of real-world data, J Clin Med, doi:10.3390/jcm9051515
Safavi, Nath, Silencing of immune activation with methotrexate in patients with COVID-19, J Neurol Sci, doi:10.1016/j.jns.2020.116942
Sara, ICU and ventilator mortality among critical ill adults with coronavirus disease 2019, Critical Care Medicine, doi:10.1097/ccm.0000000000004457
Waleed, Kassar, Aref, Afif, Azithromycin promising medicine for COVID-19 in early stage by effecting on mTORC and immune system
Woloshin, Patel, Skesselhein, False negative tests for SARS-CoV-2 infection, N Engl J Med, doi:10.1056/nejmp2015897
Zhang, Xiao, Zhang, Xia, Cao et al., NEJM coagulopathy and antiphospholipid antibodies in patients with Covid-19, doi:10.1056/nejmc2007575
Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in china, N England J Med, doi:10.1056/nejmoa2001017
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop